Therapeutic advances changed dramatically in 2010 with the U.S. FDA approval of the autologous cellular immunotherapy sipuleucel-T for the treatment of men with asymptomatic or minimally symptomatic metastatic CRPC. This is an updated review on the data regarding therapeutic options with particular focus on the emerging strategies for incorporating sipuleucel-T into this changing landscape
Most prostate cancer-related deaths occur in patients with castration-resistant prostate cancer (CRPC). Until recently, only therapy with docetaxel and prednisone has been shown to prolong survival in men with metastatic CRPC. With the United States Food and Drug Administration (US FDA) approvals of sipuleucel-T, cabazitaxel, and abiraterone acetate, all based on improvement in overall survival, the landscape for management of men with metastatic CRPC has dramatically changed. In this review we will discuss the pivotal clinical trial data leading to these approvals, with particular focus on the unique indication for sipuleucel-T and the implications for optimal management and sequencing of treatment in this patient population.
PDF (510.04 KB PDF FORMAT)
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
The editors were extremely helpful and prompt in responding to questions and issues related to the submission. The online submission was easy and quick. The whole process from submission to publication was very satisfying and expeditious.
All authors are surveyed after their articles are published. Authors are asked to rate their experience in a variety of areas, and their responses help us to monitor our performance. Presented here are their responses in some key areas. No 'poor' or 'very poor' responses were received; these are represented in the 'other' category.See Our Results
Copyright © 2013 Libertas Academica Ltd (except open access articles and accompanying metadata and supplementary files.)